Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Dr. Lee F. Allen Joins Argos Therapeutics as Chief Medical Officer
Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis
Argos Therapeutics to Participate in the ROTH Immuno-Oncology Corporate Access Day